Botanix Pharmaceuticals (ASX: BOT) has had its data on the merits of cannabinoids in dermatology independently presented at the recent annual American Academy of Dermatology (AAD) meeting in Washing DC.
Botanix is currently running Phase 2 clinical trials on acne and atopic dermatitis, and Phase 1B on psoriasis. In June 2018, they announced successful results of the Phase 1B trial on atopic dermatitis, for which there is currently no effective treatment.
Phase 1B is the safety stage of the clinical trial process, so those results did not indicate efficacy.
The AAD is the largest and most influential representative dermatological group in the United States, boasting over 20,000 members. Botanix having its data presented at the annual meeting is a positive endorsement of the companies research.
Matt Callahan, Founder and Executive Director of Botanix said, “We are very excited that key opinion leaders in dermatology are increasingly excited by the data and potential of our clinical programs in acne, atopic dermatitis and psoriasis. At a time when patients and physicians are keenly interested in discovering new therapies in cannabinoid, our clinical pipeline is the most advanced in the world and is drawing new attention from industry and potential partners.”
Botanix is a clinical stage medical dermatology company based in Perth and Philadelphia. Their key active ingredient is synthetic CBD, who Mr Callahan strongly supports the use of, “the plant is the inspiration; it’s not necessarily the source of the material that you use in the drug.”
The company completed its first acne patient studies in January 2018, and commenced a Phase 2 study in June 2018 with completion expected mid-2019. The ongoing atopic dermatitis Phase 2 study is expected to be complete in the late 2019, and finally the Phase 1B psoriasis study should be completed within a few months.